Literature DB >> 30551396

Effects of atorvastatin and/or probucol on recovery of atherosclerosis in high-fat-diet-fed apolipoprotein E-deficient mice.

Xiaokun Guo1, Lin Wang1, Xiaoshuang Xia2, Peilu Wang2, Xin Li3.   

Abstract

INTRODUCTION: We have investigated the possible effects and mechanism of atorvastatin, a statin, and/or probucol, a powerful antioxidant used to lower cholesterol before 1995, on the atherosclerosis development.
METHODS: Apolipoprotein-E-deficient (ApoE-/-) mice fed with the high fat diet were randomly divided into 3 groups (n = 10/each group): Placebo, Atorvastatin (10 mg/ kg/d), and atorvastatin (10 mg/kg/d) plus probucol (10 mg/kg/d) groups. C57BL/6 J mice were fed with normal diet as the control group (n = 10). Animals were sacrificed 10 weeks after the intervention. To evaluate the experimental atherosclerosis, blood tests were used for measuring serum lipoprotein profile, Western blots for endoplasmic reticulum (ER) stress protein expression, H&E staining for plaque lesions, immunohistology for macrophages, inflammatory cytokines, innate immune receptor TLR-4, transcription factor NF-κB, and atherosclerosis plaques.
RESULTS: Compared with the control group, ApoE-/- mice in the placebo group showed with the significantly (p < 0.05) higher levels of serum total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL) and oxidized low density lipoprotein (ox-LDL), PERK, GRP78, CHOP, IL-1β, TNF-α and NF-κB, but with the lower levels of high-density lipoprotein cholesterol (HDL) and TLR-4, and also the increase in macrophages and the aortic media collagen, and the decrease in the elastic fibers (p < 0.01). Treatment with atorvastatin recovered all these features (p < 0.05 or p < 0.01) near to the levels in the control group. In addition, the combination of atorvastatin and probucol has shown the slightly stronger effect than the use of atorvastatin alone without statistical significances when comparing most bio-markers of atherosclerosis, but with significant differences in the reduction of the plaque lesion areas and macrophages (p < 0.05).
CONCLUSIONS: Atorvastatin and/or probucol suppresses ER stress and increase the level of TLR-4, which lowers NF-κB, resulting in the recovery of atherosclerosis in the ApoE-/- mouse model.
Copyright © 2018. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Atherosclerosis; Atorvastatin; Endoplasmic reticulum stress; NF-κB; Probucol; TLR-4

Mesh:

Substances:

Year:  2018        PMID: 30551396     DOI: 10.1016/j.biopha.2018.10.184

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  6 in total

1.  Synergistic Effect of Polydatin and Polygonatum sibiricum Polysaccharides in Combating Atherosclerosis via Suppressing TLR4-Mediated NF-κB Activation in ApoE-Deficient Mice.

Authors:  Genyi Ye; Yuhao Zhao; Junfeng Zhu; Zijian Zhang; Qiong Wang; Xu Jiang; Zhenxing Wang
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-07       Impact factor: 2.650

2.  Correlation Analysis of Huayu Tongmai Decoction Intervention and Prognosis Indexes of Patients with Carotid Atherosclerosis.

Authors:  Guangqing Cheng; Xiaoni Yan; Fengmeng Wang; Chao Chen
Journal:  Evid Based Complement Alternat Med       Date:  2021-10-31       Impact factor: 2.629

3.  Salvianolic acid B attenuates the inflammatory response in atherosclerosis by regulating MAPKs/ NF-κB signaling pathways in LDLR-/- mice and RAW264.7 cells.

Authors:  Yifan Zhang; Xiaoteng Feng; Min Du; Jie Ding; Ping Liu
Journal:  Int J Immunopathol Pharmacol       Date:  2022 Jan-Dec       Impact factor: 3.298

4.  Downregulation of LncRNA NORAD promotes Ox-LDL-induced vascular endothelial cell injury and atherosclerosis.

Authors:  Weihua Bian; Xiaohong Jing; Zhiyu Yang; Zhen Shi; Ruiyao Chen; Aili Xu; Na Wang; Jing Jiang; Cheng Yang; Daolai Zhang; Lan Li; Haiyan Wang; Juan Wang; Yeying Sun; Chunxiang Zhang
Journal:  Aging (Albany NY)       Date:  2020-04-08       Impact factor: 5.682

5.  Inhibition of CDK9 attenuates atherosclerosis by inhibiting inflammation and phenotypic switching of vascular smooth muscle cells.

Authors:  Shushi Huang; Wu Luo; Gaojun Wu; Qirui Shen; Zaishou Zhuang; Daona Yang; Jinfu Qian; Xiang Hu; Yan Cai; Nipon Chattipakorn; Weijian Huang; Guang Liang
Journal:  Aging (Albany NY)       Date:  2021-06-08       Impact factor: 5.682

6.  Huotan Jiedu Tongluo Decoction Inhibits Balloon-Injury-Induced Carotid Artery Intimal Hyperplasia in the Rat through the PERK-eIF2α-ATF4 Pathway and Autophagy Mediation.

Authors:  Tenghui Tian; Keying Yu; Miao Zhang; Xiao Shao; Liping Chang; Rui Shi; Baojin Yao; Yue Deng
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-20       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.